CN110833515B

CN110833515B - Water-in-oil system release anti-allergic polypeptide composition

Info

Publication number: CN110833515B
Application number: CN201911319251.5A
Authority: CN
Inventors: 丁文锋; 彭晏; 黄春青
Original assignee: Yutai Biology Dongguan Co ltd
Current assignee: Yutai Biology Dongguan Co ltd
Priority date: 2019-12-19
Filing date: 2019-12-19
Publication date: 2023-09-08
Anticipated expiration: 2039-12-19
Also published as: CN110833515A

Abstract

The invention discloses a water-in-oil system release and anti-allergic polypeptide composition, which belongs to the technical field of cosmetic polypeptides, wherein the release and anti-allergic polypeptide is present in a water phase, the mass percentage concentration of each polypeptide is 0.0001% -5%, and the water phase and an oil phase form a water-in-oil system. The oil phase comprises a surfactant, an oily emollient. Compared with a water-based system, the soothing and anti-allergic polypeptide composition adopts a water-in-oil system, and polypeptide components are dissolved in a small amount of water phase, so that the partial polypeptide concentration in the water-in-oil system is higher, transdermal absorption is easier, the accumulation amount of the soothing and anti-allergic polypeptide composition on skin is higher, the same feeding amount can achieve a more excellent soothing and anti-allergic effect, and the soothing and anti-allergic polypeptide composition has the advantages of good stability, high safety, simple preparation process and low cost, and is suitable for industrial mass production.

Description

Water-in-oil system release anti-allergic polypeptide composition

Technical Field

The invention belongs to the technical field of beauty polypeptides, and relates to a water-in-oil system soothing anti-allergic polypeptide composition.

Background

With the development of human society, the living standard of people is greatly improved, however, the environmental pollution is also serious, and the skin problem is endless, wherein skin sensitivity is a common skin problem with higher occurrence rate. Under the comprehensive actions of various factors in vitro and in vivo, the skin barrier function is damaged, the skin sensory nerve signal is transmitted and enhanced, the tolerance threshold is reduced, the skin is excessively stimulated and excessively reacted with weak outside, different cell types of the skin are activated to induce and release pro-inflammatory cytokines and chemokines, the vascular reactivity is enhanced, and the vascular expansion and inflammatory cell infiltration are caused, so that various sensitive skin discomfort symptoms such as red swelling, burning, tightening, itching, dryness, desquamation and the like are caused on the skin.

For care of sensitive skin, natural, non-irritating products should be used. However, various different care products are filled in the market at present, and even forbidden components such as glucocorticoid are added, so that great harm is caused to consumers, and development of an anti-allergic product with obvious efficacy, safety and no stimulation has become an important point in current cosmetic development. The polypeptide is used as an active substance which is homologous with the organism and has multiple physiological regulation functions, and is gradually and widely focused in the beauty and cosmetics industry, and is increasingly applied to the common problem of improving sensitive skin.

These antiallergic active polypeptides are all water-soluble components, so that the corresponding polypeptide products are also mostly water-based, in which the polypeptide is dissolved. However, the polypeptide is easily degraded in an aqueous solution, and the polypeptide component is directly added into a water-based product, so that there is a problem that the stability of the polypeptide in the product is poor, so that the polypeptide originally having high-efficiency activity cannot fully exert its effect, and degradation products generated by the degradation of the polypeptide in the product may potentially harm human bodies. In addition, water-soluble substances are difficult to be absorbed through the skin barrier, and thus it is difficult to sufficiently exert their soothing antiallergic effects. In order to increase transdermal absorption to achieve the desired effect, it is necessary to increase the amount of the material to be fed, thereby bringing about an increase in cost.

Therefore, there is an urgent need in the art for a product with good stability, high safety, easy transdermal absorption, simple preparation process, low cost, suitability for industrial mass production, excellent effect, and capability of overcoming the defects of the prior art.

Disclosure of Invention

The invention aims to solve the technical problems of providing the release and anti-allergic polypeptide composition which has the advantages of good stability, high safety, easiness in transdermal absorption, simple preparation process, low cost, suitability for industrial mass production and excellent effect.

Through experimental research, the polypeptide components are dispersed in the oil phase to form a water-in-oil system, a small amount of water phase in the system can reduce the contact between the polypeptide and water, so that the polypeptide is concentrated in the water phase, the stability of the polypeptide is improved, and the polypeptide with larger local concentration is beneficial to exerting better effects of relieving and resisting allergy; the external oil phase can make polypeptide component penetrate skin barrier better and promote absorption, so that the product has excellent relieving and anti-sensitization effects, and the invention is formed.

The invention provides a water-in-oil system release anti-allergic polypeptide composition, which comprises release anti-allergic polypeptide, wherein the polypeptide exists in a water phase, the mass percentage concentration of the polypeptide is 0.0001% -5%, and the water phase and the oil phase form a water-in-oil system.

The soothing anti-allergic polypeptide is selected from one or more of the following polypeptides, including but not limited to: palmitoyl tripeptide-8, palmitoyl tetrapeptide-7, acetyl tetrapeptide-15, acetyl tetrapeptide-40, acetyl tetrapeptide-33, acetyl dipeptide-1 cetyl ester, acetyl hexapeptide-49.

The oil phase of the present invention comprises a surfactant and an oily emollient.

The surfactant is one or a combination of more of PEG-20 triisostearate, PEG-7 glycerol cocoate, PEG-6 caprylic/capric glyceride, polyglycerol-2 isostearate and polyglycerol-4 laurate, and the mass percentage concentration of each component is 1-10%.

The oily emollient is one or a combination of a plurality of hydrogenated polyisobutene, caprylic/capric triglyceride and isononyl isononanoate, and the mass percentage concentration of the oily emollient is 70-90%.

The oily emollient may further comprise a vegetable oil which is camellia seed oil, jojoba seed oil, nut oil, sunflower seed oil.

The water-in-oil system soothing anti-allergic polypeptide composition is mainly used for preparing skin care products or medical products for external use.

In order to facilitate understanding of the invention, the mechanism of action of polypeptides at different action targets for the reasons of skin sensitivity is described as follows:

1. reasons for skin sensitivity

(1) The production of proinflammatory cytokines promotes the appearance of redness, swelling, heat and pain of skin. The skin is stimulated by ultraviolet light and the like, and under the induction of ultraviolet light, the production of pro-opiomelano-cotin (POMC) and alpha-melanocyte stimulating hormone (alpha-MSH) which further promote the production of pro-inflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha). Among them, IL-8 is a chemotactic cytokine that promotes chemotaxis of inflammatory cells and induces cell proliferation. TNF- α is a potent pro-inflammatory cytokine that promotes increased vascular permeability, leading to oedema and red blood streaks in the skin. Other endogenous inflammatory factors such as bradykinin, nerve growth factor, prostanoids (e.g. PGE 2), protease activated receptors (e.g. PAR-2, which cause vasodilation) are also involved in inflammation, and may cause sensitive symptoms such as redness, stinging, red blood streaks, etc. in the skin.

(2) The skin tolerance threshold is lowered, normal environmental factors cannot be tolerated, the skin has higher reactivity than normal skin, and uncomfortable feelings such as various stimulus, pain and the like are improved. Neural hyperresponsiveness is generally associated with the release of transient receptor potential vanillic acid receptor 1 (TRPV 1) and neuropeptides. TRPV1 is a ligand-gated non-selective cation channel that, upon binding to a ligand, causes Ca ²⁺ Influx, then causes a series of pathophysiological responses. TRPV1 can be stimulated by various exogenous and endogenous physical and chemical stimuli, such as high temperature (exceeding 43 ℃), low pH (acidic environment), and capsaicin (active ingredient of capsicum), and is associated with the occurrence of inflammation, and can transmit pain signals; neuropeptides are mainly calcitonin gene related peptide (CGPR). By reducing the amount of calcitonin gene related peptide (CGPR), the stimulation/excitation of neurons can be reduced, the tolerance threshold of skin can be improved, and the uncomfortable feeling of skin to various stimulation, pain and the like can be weakened.

2. Mechanism of action of polypeptides

Palmitoyl tripeptide-8 (Palmitoyl Tripeptide-8), which has affinity similar to alpha-MSH, is easy to bind with melanocortin receptor 1 (MC 1-R), can effectively inhibit release of pro-inflammatory factor interleukin-8 (IL-8) induced by UVB by binding and activating MC1-R receptor, can inhibit early steps of inflammatory cascade reaction, effectively prevent and slow down inflammation and symptoms caused by chemical stimulus, can also interfere with generation of tumor necrosis factor-alpha (TNF-alpha), prevent neurodermatitis symptoms such as edema and red blood streak, and has anti-inflammatory and soothing effects.

Palmitoyl tetrapeptide-7 (Palmitoyl Tetrapeptide-7, CAS number 221227-05-0), a fragment of immunoglobulin IgG, regulates interleukin-6 (IL-6) secretion. IL-6 participates in chronic inflammatory reaction of skin, and the increase of IL-6 accelerates skin aging, and palmitoyl tetrapeptide-7 can reduce the level of IL-6 in the skin aging process, thereby re-maintaining the balance of cytokines in skin, remarkably eliminating skin inflammation, reducing glycosylation damage, thereby playing a role in relieving, delaying skin aging, and increasing skin elasticity and compactness.

Acetyl tetrapeptide-15 (Acetyl Tetrapeptide-15), acting on the mu opioid receptor, is highly selective for the receptor. The anti-allergic agent can reduce the quantity of pro-inflammatory mediator calcitonin gene related peptide (CGPR) generated by a human body by combining with a receptor, reduce the oversensitivity of nerves to external stimulus, improve the tolerance threshold of skin, weaken uncomfortable feelings of the skin to various stimulus, pain and the like, and play a role in relieving and resisting sensitization.

Acetyl tetrapeptide-40 (Acetyl Tetrapeptide-40) can inhibit inflammatory reaction caused by antibacterial peptide LL-37, reduce interleukin-6 (IL-6) and interleukin-8 (IL-8) release, reduce cell injury and skin inflammatory injury, and reduce facial redness and telangiectasia caused by inflammation. The mechanism of action of acetyl tetrapeptide-33 (Acetyl Tetrapeptide-33) is similar.

Acetyl Dipeptide-1 cetyl ester (Acetyl Dipeptide-1 Cetyl Ester,CAS: 196604-48-5) significantly reduced prostaglandin E2 (PGE 2) secretion and nuclear transcription factor kappa B (NF- κB) signaling. PGE2 can induce inflammation, promote local vasodilation, and cause inflammation symptoms such as red swelling and pain; NF- κB is an important transcriptional regulator in cells and, when activated, induces the expression of a variety of genes, producing a variety of cytokines that are involved in inflammatory responses. Acetyl dipeptide-1 cetyl esters have anti-inflammatory and anti-allergic effects by affecting PGE2 secretion and NF- κB signaling.

Acetyl hexapeptide-49 (Acetyl Hexapeptide-49) can inhibit the activity of protease activated receptor 2 (Protease Activated Receptor 2, PAR-2). PAR-2 is an important molecule of mast cells involved in skin inflammation and hypersensitivity reactions, and acetyl hexapeptide-49 reduces skin inflammation and relieves skin itching by inhibiting PAR-2 activity.

According to the invention, from the reason of skin sensitivity, by utilizing different action targets of the polypeptide on the skin and dispersing the polypeptide in an oil phase system, the water-in-oil system release anti-allergic polypeptide composition is obtained. The beneficial effects obtained by the invention relative to the prior art include:

(1) The polypeptide is dissolved in a small amount of water phase and dispersed in oil phase to form a water-in-oil system, so that the stability and the use safety of the polypeptide are improved.

(2) The polypeptide is concentrated in the water phase, so that the concentration of local active ingredients is increased, and a better effect of relieving and resisting allergy is achieved.

(3) The oil phase in the system can promote the transdermal absorption of the water-soluble polypeptide, and the same dosage can achieve better effect of relieving and resisting allergy.

(4) The invention can achieve better effects of relieving and resisting allergy with lower cost, and the preparation process is simple and is suitable for industrial mass production.

Drawings

Microscopic image of the water-in-oil system of the polypeptide composition of fig. 1 (40 x 10 times)

FIG. 2 polypeptide cumulative transdermal and cumulative skin hold-up in vitro (24 h)

Detailed Description

For a better understanding of the present invention, the following detailed description of the invention is provided in connection with the accompanying examples and figures, but is not limited to the following examples.

Examples preparation of the compositions of examples 1-5 and comparative examples 1-5

The formulation ratios (percentages) of the compositions of examples 1-5 and comparative examples 1-5 are as follows:

methods for preparing the compositions of examples 1-5 and comparative examples 1-5:

1. accurately weighing the raw materials 5, 6, 7, 8 and 9, adding the raw material 1 with the prescription amount, and fully dissolving;

2. accurately weighing the raw materials 2, 3 and 4, and uniformly mixing the raw materials with the solution obtained in the step 1. Microscopic images of example 2 were observed using a biological digital microscope, as shown in fig. 1, and a number of droplets of uniform size were observed under a microscope at 40 x 10 x and uniformly distributed in the oil phase to form a water-in-oil system.

Test example 1 stability test

1.1 instruments

Constant temperature and humidity box, high Performance Liquid Chromatograph (HPLC)

1.2 test samples

Examples 1 to 5, comparative examples 1 to 5

1.3 test basis

Guidelines for testing stability of crude drug and preparation of four general rules 9001 of 2015 edition of Chinese pharmacopoeia

1.4 test conditions and test items

Acceleration test: the content of the polypeptide in each sample was measured by HPLC at 40.+ -. 2 ℃ and 75%.+ -. 5% RH in a constant temperature and constant humidity cabinet at 1, 2, 3 and 6 months, respectively, to evaluate the stability.

Long-term test: the content of the polypeptide in each sample was measured by HPLC at 25.+ -. 2 ℃ and 60%.+ -. 10% RH in a constant temperature and humidity oven at 3, 6, 9, 12, 18, 24, 36 months, respectively, to evaluate the stability.

1.5 stability test results

The stability data for the samples of examples 1-5, comparative examples 1-5 after 6 months of standing under accelerated test conditions are shown in Table 1 below:

TABLE 1 stability test data (content should be 95% -105% of the indicated amount) accelerated for 6 months

The stability data for the samples of examples 1-5, comparative examples 1-5 after 6 months of standing under long term test conditions are shown in Table 2 below:

TABLE 2 stability test data (content should be 95% -105% of the indicated amount) for long term 6 months

From the results shown in tables 1 and 2, the polypeptide content of example 1 was not significantly changed and was still within the quality standard after 6 months of the acceleration test and the long-term test, while the polypeptide content of comparative example 1 was significantly reduced, indicating that the polypeptide had better stability in water-in-oil systems. Similarly, comparing the results of the different tests of example 2 and comparative example 2, example 3 and comparative example 3, example 4 and comparative example 4, and example 5 and comparative example 5, it is known that the stability of the polypeptides in different types in the water-in-oil system is better than that in the water-based system, the polypeptide content in the water-based system is reduced to different degrees after the acceleration test and the long-term test for 6 months, the reduction of the polypeptide content inevitably leads to the reduction of the efficacy, and even harmful degradation products can be generated, so that the polypeptide has potential harm to human bodies. Therefore, the stability and the safety of the active polypeptide can be improved by dispersing the active polypeptide in a water-in-oil system, and more excellent relieving and anti-allergic effects can be obtained under the condition of the same dosage.

Test example 2 in vitro cumulative transdermal and cumulative skin hold-up test

2.1 instruments

Intelligent drug transdermal diffusion tester and High Performance Liquid Chromatograph (HPLC)

2.2 test samples

Example 1, comparative example 1

2.3 test methods

Samples were evaluated for transdermal properties using vertical Franz diffusion Chi Fa. The isolated skin of the abdomen of SD rat is fixed between the receiving chamber and the supply chamber of the diffusion cell, 1g sample is taken on the skin surface of the supply chamber, and the effective diffusion area is 3.14cm ² Physiological saline is added into the receiving pool as receiving liquid, and the clean bubbles are discharged to ensure that one side of the dermis is completely contacted with the receiving liquid, and the mixture is stirred and diffused at 32 ℃ and 300 r/min. And respectively taking 0.5mL of receiving solution at 4h, 8h, 12h, 16h, 20h and 24h, and timely supplementing the same amount of constant temperature blank receiving solution. The concentration of the polypeptide in the receiving liquid is measured by HPLC, and the accumulated transdermal quantity of the polypeptide per unit area at different times is calculated according to the following formula:

wherein: q (Q) _n To accumulate transdermal flux; c (C) _n The concentration of the polypeptide in the receiving liquid is obtained during the sampling; v is the volume of normal saline in the receiving tank; c (C) _i The concentration of the polypeptide in the receiving liquid is the 1 st time to the last sampling; v (V) _i For each sample volume; a is the effective diffusion area.

After 24 hours, the skin is taken off, the residual liquid of the sample is washed off by ultrapure water, then sheared, ultrapure water is added for homogenization treatment, ultrasound is carried out for 5min, centrifugation is carried out for 10min at 10000r/min, the supernatant is taken and detected by an HPLC method, and the skin retention of the polypeptide unit area is calculated according to the following formula:

Q _s ＝C _s ×V/A

wherein Q is _s Is the accumulated hold-up; c (C) _s The mass concentration of the polypeptide in the skin sample liquid is measured at a sampling time point; v is the volume of the supernatant; a is the effective diffusion area.

2.4 test results

Example 1, comparative example 1 the in vitro cumulative transdermal and cumulative skin hold up of the polypeptides in the samples after 24h transdermal diffusion test are shown in figure 2.

FIG. 2 shows that the cumulative transdermal amount of the polypeptide component of example 1 over 24 hours is 66.48. Mu.g/cm ² Cumulative skin hold up was 35.26 μg/cm ² The polypeptide component of comparative example 1 was subjected toThe cumulative transdermal flux for 24 hours was 25.73. Mu.g/cm ² Cumulative skin hold up at 6.14 μg/cm ² . Therefore, the polypeptide is directly dissolved in the water-based system, the water-soluble polypeptide is difficult to penetrate the skin barrier due to the limitation of the skin barrier, the transdermal quantity and the skin retention are low, the polypeptide is easier to be absorbed in the skin by virtue of the similar principle of the oil phase and the skin barrier after being dispersed in the oil phase, and the polypeptide component is dissolved in a small amount of water phase, so that the local polypeptide concentration in the water-in-oil system is higher, and the increase of the concentration gradient is also beneficial to promoting the transdermal absorption. The comparison test result shows that the polypeptide is dispersed in the water-in-oil system, the transdermal quantity and the skin retention are obviously improved, and especially the skin retention is obviously improved, and the polypeptide can be accumulated in the skin to form an active ingredient reservoir, so that the anti-allergic effect can be effectively and permanently exerted.

Test example 3 anti-inflammatory test

3.1 materials and instruments

NCTC cells (keratinocytes from normal human skin), DMEM medium, fetal bovine serum, concentration 10 ^- ¹¹ M alpha-MSH, samples of examples 1-5, ELISA kit, carbon dioxide incubator

3.2 test methods

NCTC cells were added to DMEM medium (containing 5% fetal calf serum) and placed in a medium containing 5% CO ₂ Culturing in a carbon dioxide incubator with the humidity of 95% and the constant temperature of 37 ℃ for 48 hours, replacing the culture solution, taking out the culture solution after cells grow into a culture bottle, discarding the culture solution, adding about 3mL of digestive juice to cover the bottom of the bottle to limit the limit, adding a DMEM culture medium to terminate the reaction after the cytoplasm is found to retract and the cell gap is increased after about 2-3min, and preparing the single cell suspension.

NCTC cells were treated with UVB irradiation and cultured in medium containing α -MSH, samples of examples 1-5, and PBS, respectively, for 24h. The cell suspension was diluted with PBS (pH 7.2-7.4). By repeated freeze thawing, cells are destroyed and intracellular components are released. Centrifuging and carefully collecting the supernatant for later use.

The IL-8 content of the sample is calculated by a standard curve by measuring the optical density value (OD value) of each well at a wavelength of 450nm by an enzyme-labeled instrument after sample addition, incubation, washing, enzyme addition, incubation, washing, color development and termination reaction by using an IL-8ELISA kit according to the operation steps of the specification. The α -MSH group and the examples 1-5 groups were compared with the blank group, respectively, and the IL-8 release amount relative to the blank group was calculated, and the percent change in the IL-8 release amount after the treatment with the remaining groups of samples was calculated.

3.3 test results

The percent change in IL-8 release after treatment in the alpha-MSH group, examples 1-5, relative to the IL-8 release in the blank is shown in Table 3 below.

TABLE 3 percent change in IL-8 release after treatment of each set of test samples

From the results in Table 3, it can be seen that the release of IL-8, which is an inflammatory mediator induced by UVB irradiation, was reduced by 41.36% relative to the blank, indicating that the polypeptide has an efficacy similar to that of alpha-MSH, and is capable of reducing the release of IL-8, which is an inflammatory mediator induced by UVB irradiation, and thus inhibiting the neurogenic inflammatory response. In addition, under the condition that the concentration of the active ingredients is kept consistent, the change percentage of the release amount of the IL-8 is gradually increased along with the increase of the types of the polypeptides, so that the release of the IL-8 can be obviously reduced, and the obvious synergistic effect between different polypeptides is shown, so that a better anti-inflammatory effect can be achieved.

Test example 4 clinical trial for evaluating the effect of soothing anti-sensitization

4.1 subject

330 healthy volunteers, aged in the range of 25-30 years, had obvious redness, swelling, inflammation, itching, etc. on their faces and could not be cured for a long time. These volunteers were randomly divided into 11 groups, with an average of 30 persons per group.

4.2 test samples

Examples 1-5, comparative examples 1-5, with placebo as a blank.

4.3 test methods

After cleansing the face in the morning and evening, the samples of examples 1-5, comparative examples 1-5, and placebo were applied once in the morning and evening, respectively, for 4 weeks. Objective symptoms of the patient were recorded in detail before and after treatment.

4.4 efficacy evaluation index

The soothing and antiallergic effects of the samples were evaluated from objective indicators.

The objective evaluation index is as follows: a. the clinical symptoms such as redness, swelling, dryness, desquamation and the like are used as evaluation standards, the grade is scored according to the degree of softness, and the degree of absence, the degree of softness, the degree of moderate and the degree of severity are respectively scored as 0-3 points.

4.5 test results

The objective evaluation scores before and after use of each group of volunteers are shown in Table 4.

Table 4 objective evaluation score before and after use of each group of volunteers

As can be seen from the data in the tables, the objective evaluation scores of the volunteers in examples 1 to 5 and comparative examples 1 to 5 all showed different degrees of decrease after 4 weeks of use relative to the placebo group, indicating improvement of symptoms such as redness, swelling and inflammation of the skin of the volunteers, and the polypeptides had a soothing and antiallergic effect. Comparing the scoring results of example 1 with that of comparative example 1, under the condition that the types and the dosage of the polypeptides are the same, the objective evaluation score of the volunteer of example 1 is lower after 4 weeks of use, and the reduction range is larger, and the evaluation score is reduced by 27.63%, so that the soothing and antiallergic effect of example 1 is obviously better than that of comparative example 1, which means that the polypeptides are dispersed in an oil phase system and are easier to be absorbed transdermally, thereby exerting more excellent soothing and antiallergic effect, and the polypeptide components are dissolved in a small amount of water phase, so that the local polypeptide concentration in the water-in-oil system is higher, which is also beneficial to the polypeptides to exert the soothing and antiallergic effect better. Similarly, comparison of the different scoring results and the percentage of scoring change of the example 2 and the comparative example 2, the example 3 and the comparative example 3, the example 4 and the comparative example 4, and the example 5 and the comparative example 5 shows that the relaxing and antiallergic effects of the polypeptides of different types in the water-in-oil system are better than those in the water-based system. In addition, under the condition that the concentration of the active ingredients is kept consistent, the objective evaluation score of corresponding volunteers is also reduced more after 4 weeks of use along with the increase of the types of the polypeptides, which indicates that different polypeptides can exert efficacy from different action targets, and each polypeptide has obvious synergistic effect, so that more excellent effect of relieving and resisting sensitization can be achieved.

The foregoing is a further detailed description of the invention in connection with the preferred embodiments, but is not intended to limit the practice of the invention to such description. It will be apparent to those skilled in the art that several simple deductions or substitutions can be made without departing from the spirit of the invention, and the invention is not limited to the above-mentioned embodiments.

Claims

1. A water-in-oil system soothing anti-allergic polypeptide composition, which is characterized in that the soothing anti-allergic polypeptide exists in an aqueous phase, the mass percentage concentration of the soothing anti-allergic polypeptide is 0.15%, and the aqueous phase and an oil phase form a water-in-oil system; the bradykinin is a combination of palmitoyl tripeptide-8 and palmitoyl tetrapeptide-7, or a combination of palmitoyl tripeptide-8, palmitoyl tetrapeptide-7 and acetyl tetrapeptide-15, or a combination of palmitoyl tripeptide-8, palmitoyl tetrapeptide-7, acetyl tetrapeptide-15 and acetyl tetrapeptide-40, or a combination of palmitoyl tripeptide-8, palmitoyl tetrapeptide-7, acetyl tetrapeptide-15, acetyl tetrapeptide-40 and acetyl dipeptide-1 cetyl ester; the oil phase consists of PEG-6 caprylic acid/capric acid glyceride, polyglycerol-4 laurate and hydrogenated polyisobutene, wherein the mass percentage concentration of the PEG-6 caprylic acid/capric acid glyceride is 5%, the mass percentage concentration of the polyglycerol-4 laurate is 10%, and the mass percentage concentration of the hydrogenated polyisobutene is 80%.

2. Use of a water-in-oil soothing anti-allergic polypeptide composition according to claim 1 for the preparation of a skin care product for external application to the skin.